Feature | Category | Baseline biopsy specimen | On-treatment biopsy specimen | ||
Low TC (n=13, 23%) | High TC (n=44, 77%) | Low TC (n=15, 26%) | High TC (n=42, 74%) | ||
Sex | Female | 2 (15) | 24 (55) | 3 (20) | 23 (55) |
Male | 11 (85) | 20 (45 | 12 (80) | 19 (45) | |
Age (years) | Mean Range | 51 26–80 | 56 24–86 | 53 24–78 | 55.2 24–86 |
Trial cohorts | Carcinoma of unknown primary | 1 (8) | 8 (18) | 2 (13) | 7 (17) |
Skin squamous cell carcinoma | 3 (25) | 6 (14) | 5 (33) | 4 (10) | |
Germ cell tumor/testicular tumor | 2 (17) | 4 (9) | 1 (6) | 5 (12) | |
Adrenocortical carcinoma | 0 (0) | 5 (11) | 0 (0) | 5 (12) | |
Paraganglioma/pheochromocytoma | 1 (8) | 4 (9) | 2 (13) | 3 (7) | |
Small cell malignancies of non-pulmonary origin | 1 (8) | 3 (7) | 1 (6) | 3 (7) | |
Medullary renal cell carcinoma | 1 (8) | 1 (2) | 1 (6) | 1 (2) | |
Penile carcinoma | 0 (0) | 1 (2) | 0 (0) | 1 (2) | |
Vascular sarcoma | 1 (8) | 0 (0) | 1 (6) | 0 (0) | |
Other rare tumors | 3 (25) | 12 (27) | 2 (6) | 13 (31) | |
Response | CR | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PR | 0 (0) | 6 (14) | 3 (2) | 3 (7) | |
SD (≥6 months) | 0 (0) | 7 (16) | 3 (2) | 5 (12) | |
SD (<6 months) | 3 (25) | 2 (5) | 2 (1) | 2 (5) | |
PD | 10 (83) | 29 (66) | 7 (47) | 32 (76) | |
Clinical benefit rate (PR or SD >6 months) | 1 (8) | 13 (30) | 6 (40) | 8 (19) |
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TC, tumor content.